Novel lipid altering therapies will steer acute coronary syndrome market beyond $12 billion by 2022

12-Aug-2016 - The acute coronary syndrome (ACS) market is set to rise from $7.8 billion in 2015 to $12.1 billion by 2022, at a relatively strong compound annual growth rate of 4.6%. The launch of several new lipid targeting therapies which offer clinical effectiveness for statin intolerant patients and ...

FDA advisory committee recommends approval of Sanofi treatment for adults with type 2 diabetes

30-May-2016 - Sanofi announced today that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. Food and Drug Administration (FDA) recommended the approval of the New Drug Application (NDA) for the investigational fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 ...

Ezetimibe reduces cardiovascular events in diabetics with recent acute coronary syndrome

01-Sep-2015 - New data from a clinical trial led by cardiologists at Brigham and Women's Hospital (BWH) and the Duke Clinical Research Institute indicates that the non-statin, cholesterol-lowering drug ezetimibe, when added to a statin in patients admitted to the hospital with an acute coronary syndrome, ...

Ablynx reports phase II dara for ALX-0081 in high risk ACS patients undergoing a PCI procedure

16-Nov-2011 - Ablynx announced head-line data from a proof-of-concept (POC) Phase II study with the anti-vWF Nanobody, ALX-0081, in high risk patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). In this multi-national, multi-institutional, open-label Phase II study, ...

First Patient Dosed in Phase II Clinical Trial for BioInvent's Cardiovascular Drug, BI-204

Trial start triggers US$ 15 million milestone from Genentech

16-Mar-2011 - BioInvent International AB announced the dosing of the first patient in the phase II study of the Company’s antibody, BI-204. The product candidate is being developed for secondary prevention of cardiovascular events in patients with acute coronary syndrome.The Phase II study is a multicenter, ...

BioInvent announces approval to start Phase II trial for its novel cardiovascular drug BI-204

12-Nov-2010 - BioInvent International AB announced IND clearance from the U.S. Food & Drug Administration (FDA) to initiate a Phase II study for BI-204. BI-204 is a human monoclonal antibody that specifically targets oxidized forms of a low-density lipoprotein (LDL) which has been linked to increased ...

Takeda Announces Top Line Results from Phase 2 Study of Investigational Compound, TAK-442 for the patients with ACS

28-Oct-2010 - Top line data from a phase 2 study of TAK-442, an oral anticoagulant, biologically active factor Xa inhibitor (fXai), under investigation by Takeda, are now available. This phase 2, multi-center, randomized double blind, placebo-controlled study conducted globally except in Japan was designed to ...

Cerenis Therapeutics raises additional €10 million to close €50 million Series C financing

22-Oct-2010 - Cerenis Therapeutics announced it has raised a further €10 million in a second close of its Series C financing. This takes the total funds raised in the Series C to €50 million and the total equity investment raised to date by the Company to €117 million. The latest €10 million came from the ...

IMS HEALTH Forecasts Global Pharmaceutical Market Growth of 5-7 Percent in 2011, Reaching $880 Billion

Patent expiries and new wave of drug budget controls subdue growth among brands in developed markets

15-Oct-2010 - The value of the global pharmaceutical market is expected to grow 5-7 percent in 2011, to US$880 billion, compared with a 4-5 percent pace this year, according to IMS Health. The forecast, included in the latest release of IMS Market Prognosis™, is the leading annual industry indicator of market ...

Cerenis and Novasep awarded €10.7 million funding from the French Government for the development CER-001, an HDL mimetic

27-Jul-2010 - Cerenis Therapeutics SA and Groupe Novasep announced that they have received French Government funding through OSEO to finance the development of CER-001, a Cerenis HDL mimetic. CER-001 represents a promising new approach in the fight against atherosclerotic cardiovascular disease and has shown ...